FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896152547> ?p ?o ?g. }

• W2896152547 endingPage "e446" @default.
• W2896152547 startingPage "e446" @default.
• W2896152547 abstract "The aim of the study is to evaluate treatment result of cancer patients (pts) with oligometastatic disease. Additional identification of prognostic and predictive factors was also performed. Inclusion criteria were: histological confirmation of cancer, one to three metastases (mets), except brain mets, stereotactic radiotherapy (SBRT) as local treatment of metastatic lesion, at least one follow-up (FU) visit. Group consisted of 542 consecutive cancer pts (186 female, 356 male; age 21-85, median 66) treated in 2004 – 2017 with SBRT due to 698 mets, including 241 lung (35%), 227 lymph node (32%), 106 bone (15%), 105 liver (15%) and 19 adrenal/soft tissue mets (3%). Median time to develop mets was 21 months after the primary diagnosis (range 0-315). Majority (91%) received primary radical treatment. SBRT total dose ranged from 6 to 60 Gy (median 36) delivered in fractions of 5 to 20 Gy (median 12). In statistical analysis Kaplan - Meier method, log rank test and multivariate Cox regression model were used. Follow-up (FU) ranged from 0.3 to 28.8 years (median 14.2) from primary diagnosis, from 0.3 to 17.2 years (median 6.6) from mets diagnosis and 0.1 to 9.8 years from mets SBRT (median 5.6). Five-, 10-, and 15-year overall survival (OS) was 81%, 61% and 46%, respectively. Local control after SBRT was achieved in 91% pts and remained stable to the end of FU in 80%. Other mets occurred in 51% of pts after SBRT. Multivariate analysis showed that time of mets detection (oligometastases vs oligorecurrence, p=0.000), age (p=0.03), type of treatment of primary tumor (radical vs palliative, p=0.000), location of mets (p=0.002) and performance status (p=0.001) are significant factors influencing OS. Patients in oligometastatic group had 5-year OS from SBRT of 37% compared to 58% in oligorecurrence group (p=0.0003). Lung and gastrointestinal cancer pts are those who benefit the most from implementation of radical therapy in primary treatment (p=0.000 and 0.003, respectively). SBRT responders with liver and lymph node mets had better OS (p=0.0002 and 0.0099, respectively) and those with liver, bone and lung mets had improved PFS (p=0.0001, 0.011 and 0.003, respectively) compared to non-responders. Type of primary treatment (p=0.000), type of cancer (p=0.04) and performance status (p=0.02) were significant factors influencing PFS after SBRT in multivariate analysis. Type of cancer (p=0.006), location of mets (p=0.013) and presence of other than treated with SBRT mets (p=0.026) were significant factors influencing LC after SBRT in multivariate analysis. LC and PFS was better in pts with SBRT total dose over 50 Gy (p=0.008 and 0.0008, respectively). Primary radical treatment of oligometastatic cancer pts in SBRT mets group improved OS and PFS, and should be applied in those in good performance status. Patients with oligometastases had inferior OS compared to oligorecurrence group." @default.
• W2896152547 created "2018-10-26" @default.
• W2896152547 creator A5043267220 @default.
• W2896152547 creator A5071051754 @default.
• W2896152547 creator A5085223650 @default.
• W2896152547 date "2018-11-01" @default.
• W2896152547 modified "2023-10-01" @default.
• W2896152547 title "Oligometastases – New Era of Cancer Therapy?" @default.
• W2896152547 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1291" @default.
• W2896152547 hasPublicationYear "2018" @default.
• W2896152547 type Work @default.
• W2896152547 sameAs 2896152547 @default.
• W2896152547 citedByCount "0" @default.
• W2896152547 crossrefType "journal-article" @default.
• W2896152547 hasAuthorship W2896152547A5043267220 @default.
• W2896152547 hasAuthorship W2896152547A5071051754 @default.
• W2896152547 hasAuthorship W2896152547A5085223650 @default.
• W2896152547 hasConcept C121608353 @default.
• W2896152547 hasConcept C126322002 @default.
• W2896152547 hasConcept C143998085 @default.
• W2896152547 hasConcept C2776256026 @default.
• W2896152547 hasConcept C2780192828 @default.
• W2896152547 hasConcept C2780387249 @default.
• W2896152547 hasConcept C2780849966 @default.
• W2896152547 hasConcept C2989005 @default.
• W2896152547 hasConcept C38180746 @default.
• W2896152547 hasConcept C50382708 @default.
• W2896152547 hasConcept C509974204 @default.
• W2896152547 hasConcept C71924100 @default.
• W2896152547 hasConceptScore W2896152547C121608353 @default.
• W2896152547 hasConceptScore W2896152547C126322002 @default.
• W2896152547 hasConceptScore W2896152547C143998085 @default.
• W2896152547 hasConceptScore W2896152547C2776256026 @default.
• W2896152547 hasConceptScore W2896152547C2780192828 @default.
• W2896152547 hasConceptScore W2896152547C2780387249 @default.
• W2896152547 hasConceptScore W2896152547C2780849966 @default.
• W2896152547 hasConceptScore W2896152547C2989005 @default.
• W2896152547 hasConceptScore W2896152547C38180746 @default.
• W2896152547 hasConceptScore W2896152547C50382708 @default.
• W2896152547 hasConceptScore W2896152547C509974204 @default.
• W2896152547 hasConceptScore W2896152547C71924100 @default.
• W2896152547 hasIssue "3" @default.
• W2896152547 hasLocation W28961525471 @default.
• W2896152547 hasOpenAccess W2896152547 @default.
• W2896152547 hasPrimaryLocation W28961525471 @default.
• W2896152547 hasRelatedWork W1963620108 @default.
• W2896152547 hasRelatedWork W1968616711 @default.
• W2896152547 hasRelatedWork W2167960661 @default.
• W2896152547 hasRelatedWork W2321033326 @default.
• W2896152547 hasRelatedWork W2395953112 @default.
• W2896152547 hasRelatedWork W2587755700 @default.
• W2896152547 hasRelatedWork W2747510197 @default.
• W2896152547 hasRelatedWork W2793295628 @default.
• W2896152547 hasRelatedWork W3039910633 @default.
• W2896152547 hasRelatedWork W3092660163 @default.
• W2896152547 hasVolume "102" @default.
• W2896152547 isParatext "false" @default.
• W2896152547 isRetracted "false" @default.
• W2896152547 magId "2896152547" @default.
• W2896152547 workType "article" @default.